key: cord-0784860-jf2gzjvj
authors: Serra‐García, Laura; Bosch‐Amate, Xavier; Alamon‐Reig, Francesc; Giavedoni, Priscila; Fuertes, Irene; Morgado‐Carrasco, Daniel; Iglesias, Pablo; Puig, Susana; Mascaró Jr, José M.
title: Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatment
date: 2020-10-11
journal: Int J Dermatol
DOI: 10.1111/ijd.15239
sha: 6799a14a4fcee945bea7685554f2c5c0ac9cda7a
doc_id: 784860
cord_uid: jf2gzjvj

nan

A heavy-smoker, 48-year-old woman with a history of hypertension and an unresectable facial basal cell carcinoma, receiving cemiplimab 350 mg intravenously every 3 weeks in a clinical trial (REGN-1620), because of tumoral progression and side effects from treatment with vismodegib, presented in January 2020 (17 months after initiating cemiplimab) with de novo erythematous papulonodular lesions, pallor, and cyanosis on fingertips. She was diagnosed with idiopathic chilblains and Raynaud's phenomenon, which resolved after cold avoidance strategies. In April 2020, she presented at the Emergency Department with painful digital distal ulcers. She denied having COVID-19-related respiratory symptoms. Physical examination showed white-grayish coloration with a necrotic scar and bullae formation on the second, third, and fourth fingertips of the right hand, and erythema with a punctiform necrotic scar on the fifth fingertip of the left hand ( Fig. 1 ).

RT-PCR and serologic tests for COVID-19 were performed, revealing negative PCR, positive IgG, and negative IgM antibodies. Blood tests showed high D-Dimer levels (2,500 ng/ ml, reference value <500) and low titer (1:40) antinuclear antibodies. Systemic sclerosis and antiphospholipid syndrome antibodies were negative. Angiotensin-converting enzyme inhibitors and beta-blockers were stopped, while amlodipine 10 mg b.i.d. and topical 0.2% nitroglycerin were prescribed for 3 weeks. The lesions worsened with progressive fingertip ischemia, cemiplimab treatment was stopped, amlodipine was changed for nifedipine 10 mg every 8 hours, which was tapered later on to 10 mg daily, aspirin 100 mg daily was started, and ciprofloxacin 500 mg b.i.d. and clindamycin 300 mg b.i.d. were prescribed for 2 weeks. Five days after, given the poor response, the patient was admitted to receive intravenous alprostadil 30 mg b.i.d. and wound care. Significant improvement of cutaneous lesions was observed within 1 week of this regimen (Fig. 2) , prolonged for 10 days on an outpatient basis.

Patients with COVID-19 may present with altered coagulation parameters, such as elevated D-Dimer and longer prothrombin time, which have been associated with poor prognosis. 3 Unilateral livedo reticularis, Raynaud's phenomenon, retiform purpura, and acro-ischemic skin lesions have previously been described. The latter have been associated with severe disease and poor prognosis. 1 The exact pathophysiological pathways leading to this procoagulant state are still unclear. SARS-CoV-2 uses angiotensin-converting enzyme-2 receptor in pneumocytes to infect the hosts, which is widely expressed in endothelial cells, facilitating their infection and causing diffuse endotheliitis. Some reports suggest a generalized thrombotic microvascular injury mediated by complement 

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19